Non-invasive assessment of liver fibrosis progression in hepatitis C patients retreated for 96 weeks with antiviral therapy: a randomized study

Autor:	Gérard Babany, P. Melin, A Pinta, Michèle Chevallier, Jean-Pierre Zarski, Nathalie Sturm, Corinne Bonny, Philippe Sogni, Stéphanie Rouanet, Alice Cheveau, Hervé Desmorat, J.-J. Raabe
Rok vydání:	2010
Předmět:	METAVIR Fibrosis Score medicine.medical_specialty Pathology Hepatology medicine.diagnostic_test business.industry Hepatitis C medicine.disease Gastroenterology Maintenance therapy Fibrosis Internal medicine Predictive value of tests Biopsy medicine Clinical endpoint Hepatic fibrosis business
Zdroj:	Liver International. 30:1049-1058
ISSN:	1478-3231 1478-3223
Popis:	Background The efficacy of a maintenance therapy in non-responder patients with chronic hepatitis C has been essentially evaluated by histological semiquantitative scores. Aim The aim was to evaluate the efficiency of 2 years of treatment with peginterferon alpha-2a vs alpha-tocopherol in these patients by histology, morphometry and blood markers of fibrosis. Method Hundred and five HCV patients with a Metavir fibrosis score > or = 2 were randomized to receive peginterferon alpha-2a 180 microg/week (PEG) (n=55) or alpha-tocopherol (TOCO) 1000 mg/day (n=50) for 96 weeks. The primary endpoint was improvement or stabilization of the Metavir fibrosis score by biopsy performed at week 96. Secondary endpoints included a quantitative assessment of fibrosis by morphometry and changes in blood markers of fibrosis. Results There was no difference at baseline between PEG and TOCO according to the metavir (83.3 vs 86.8%, P=0.751) stage. The median fibrosis rate, measured with morphometry was 2.72 and 2.86% at day 0, and 3.66 and 2.82% at week 96, in the PEG and TOCO groups (P=0.90) respectively. However, the percentage of patients with metavir activity grade improvement was significantly higher in the PEG group vs the TOCO group (52.8 vs 23.7%, P=0.016). Non-invasive markers analysis did not show any significant change in both groups. Conclusion Long-term therapy with peginterferon alpha-2a did not reduce liver fibrosis degree assessed by morphometry and blood tests as compared with alpha-tocopherol. Blood tests could be useful to assess liver fibrosis changes in clinical trials.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::2263c5b8b02b8761179f6334dd1d0acc https://doi.org/10.1111/j.1478-3231.2010.02265.x Zobrazit plný text záznamu Plný text ve formátu PDF